Anti-malarial Drugs Market Emerging Growth By Top Players Ipca Laboratories Ltd., Zydus Cadila, Merck KGaA Pfizer, GlaxoSmithKline Plc., Cipla Ltd, Ranbaxy Laboratories, Novartis AG, Alvizia Health Care, Bayer AG

Malaria is common infectious disease caused by the protozoan parasite, Plasmodium parasites. The bite of an infected female Anopheles mosquito transmits a parasite to the person’s body, which then enters into the person’s liver where the production of parasite occurs. Human malaria are generally caused by five types of plasmodium parasites, including P. falciparum, P. malariae, P. ovale, P. vivax, and P.knowlesi. Among these, P. falciparum and P. vivax are the most dangerous species of parasite causing highest number of malaria mortality.

PDF Brochure of This Business Research Report:
https://www.coherentmarketinsights.com/insight/request-pdf/3726

Early diagnosis and efficient treatment are crucial measures to control malaria. Different types of drugs such as quinine, chloroquine, mefloquine, proguanil, primaquine, and others are used in the treatment of malaria. Moreover, some combination drugs such as Pyrimethamine & sulfadoxine, Artemether & lumefantrine, and others are also prescribed for treating the disease. According to the World Health Organization (WHO), around 91 countries and territories are at the risk of malaria transmission.

The increasing number of regulatory approvals and launches of anti-malaria drugs is expected to propel growth of the global anti-malarial drugs market over the forecast period. For instance, in July 2018, GSK and Medicines for Malaria Venture (MMV) received the U.S. FDA approval for Krintafel (tafenoquine), a first single dose medicine to prevent the relapse of P. vivax malaria marks. Moreover, in July 2017, Cipla and Medicines for Malaria Venture (MMV) launched Artesunate Rectocaps/Rectal Artesunate Suppositories (RAS), a drug used for the treatment of severe malaria in young children.

Launching of anti-malaria drugs in the malaria affected areas such as African countries such as Uganda and other South-east Asian countries is expected to drive growth of the anti-malarial drugs market. For instance, in April 2019, Shin Poong Pharmaceutical Co.Ltd, South Korea, and Medicines for Malaria Venture (MMV) launched Pyramax, an anti-malarial drug combination of pyronardine and artesunate, in Uganada. Moreover, in December 2014, Ranbaxy Laboratories Limited launched Synriam, a new anti-malarial drug, in 7 African countries including Nigeria, Uganda, Senegal, Cameroon, Guinea, Kenya, and Ivory Coast. Moreover, in April 2012, the drug was approved by the Drug Controller General of India (DCGI) for marketing in India.

Request For Customization Of This Business Research Report:
https://www.coherentmarketinsights.com/insight/request-customization//3726

Competitive Landscape

Key players operating in the global anti-malarial drugs market include Ipca Laboratories Ltd., Zydus Cadila, Merck KGaA Pfizer, GlaxoSmithKline Plc., Cipla Ltd, Ranbaxy Laboratories, Novartis AG, Alvizia Health Care, Bayer AG, and Roche Inc.

Detailed Segmentation:

By Drug Class:
Aminoquinolines
Quinoline-methanol (4-quinolinemethanols)
Cinchona Alkaloids
Biguanides
Sulfonamides and sulfones
Others

By Route of Administration:
Oral
Injectable

By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Apply Promo Code “STAYHOME” and Get Up to 30% Discount

Buy This Complete A Business Report:
https://www.coherentmarketinsights.com/insight/buy-now/3726

Coherent Market Insights 1001 4th Ave,
#3200 Seattle, WA 98154,U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.